Navigation Links
BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
Date:2/16/2012

RALEIGH, N.C. and CHADDS FORD, Pa., Feb. 16, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance of BDSI's patent application (No. 13/184306) that, once formally granted, will extend the exclusivity of the BioErodible MucoAdhesive (BEMA) drug delivery technology for BEMA Buprenorphine and BEMA Buprenorphine/Naloxone from 2020 to 2027. 

A Notice of Allowance is issued when the USPTO has determined to grant a patent.  Once the issue fee is paid, the final granting of the patent takes place, typically within a few months.

As a part of BDSI's recently signed BEMA Buprenorphine licensing and development agreement with Endo Pharmaceuticals (Nasdaq: ENDP), BDSI is entitled to a milestone payment in the amount of $15 million upon the final granting of this patent. 

"We are very pleased by the allowance of this patent application by the USPTO, that will not only provide non-dilutive capital to BDSI in the next couple months, but importantly extends the period of exclusivity, and thus the potential for a longer royalty stream, for BEMA Buprenorphine in its use for treating chronic pain following FDA approval and commercial launch," stated Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  "It is an added benefit that this patent upon granting will afford similar protection to BEMA Buprenorphine/Naloxone for the treatment of opioid dependence."

"Endo is committed to serving as an integrated solutions provider for the development and commercialization of products focused on the management of pain," said Dr. Ivan Gergel, M.D., executive vice president, R&D and chief scientific officer, Endo Pharmaceuticals. "And the allowance of t
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
2. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
3. BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector
4. Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
8. Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region
9. Excel Life Sciences Joins DATATRAKs Connect Partner Program
10. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
11. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... According to new market research report "Cloud ... Deployment & Support), by Service Model (SaaS, PaaS, ... (Hybrid & Community)) - Global Forecast to 2019", ... Professional Services Market into various sub-segments with an ... identifies the drivers and restraints for this market ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... million which brings Q3 orders to $5.8 million and provides a ... projects in North America and one in ... to bid new projects at record levels," said Peter Bruijns ... higher at the end of Q3 than they have been for ...
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
Breaking Biology Technology:Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... , , , , ALISO VIEJO, ... VRX ) today reported final results for its Phase IIb ... is in development for the treatment of chronic hepatitis C ... treatment naive genotype 1 infected subjects was of standard design, ...
... activity in breast cancer patients with high expression of ... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, presented data from a ... in combination with the chemotherapeutic docetaxel in patients with ...
... ... crops Knowledge Platform ,CJP,s "3rd Global Jatropha Hi-Tech Agricultural Training Programme ... provide the most authoritative Knowledge platform for Development of Sustainable Non-Food ... Biodiesel Industry Worldwide. The biodiesel industry has met a lot of ...
Cached Biology Technology:Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 2Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 4Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 2Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 3Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 4Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 5Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 2Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 3Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 4
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... Law Enforcement Data Sharing Consortium Now Includes over ... International, Inc. (OTC Bulletin Board: BKYI), a leader ... solutions, today announced a contract award from the ... law enforcement mobile data solution. Using MobileCop on ...
... The New Jersey Chapter of the American Society of ... Year Award to John Schuring, Stabile Professor for Innovation ... as an expert, contact Sheryl Weinstein at 973-596-3436.) ... environmental engineering, has 35 years of experience in the ...
... ago, the oil tanker Exxon Valdez was exiting Alaska,s Prince ... of the night. What happened next is considered one of ... oil spilled into the pristine Alaskan waters, eventually covering 11,000 ... times the amount of oil spilled in the Exxon Valdez ...
Cached Biology News:Tulsa County Sheriff Selects BIO-key(R) Mobile Data System 2Civil engineers name NJIT's John Schuring Educator of Year 2UCSB scientists document fate of huge oil slicks from seeps at coal oil point 2UCSB scientists document fate of huge oil slicks from seeps at coal oil point 3UCSB scientists document fate of huge oil slicks from seeps at coal oil point 4
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
Imject Freund's Complete Adjuvant (FCA)...
... stain was developed specifically for reduced mutagenicity ... DNA in agarose or acrylamide gels. SYBR Safe ... bromide but SYBR Safe stain's detection sensitivity is ... stain comes as a premixed solution that can ...
... nucleic acid gel stain is an exceptionally ... fluorescence when bound to dsDNA and low background ... in gels using laser scanners or standard UV ... also found uses in capillary electrophoresis, real-time PCR ...
Biology Products: